Viral Vector Manufacturing Market Highlights
The global viral vector manufacturing market is expected to exhibit a strong 22.65% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The report forecasts a valuation of USD 319 million for the market by the end of the 2018-2023 forecast period.
Latest Free Sample Copy Available @ https://www.marketresearchfuture.com/sample_request/6890
The report takes a close look at historical factors enabling growth of the viral vector manufacturing market and presents a detailed analysis of the market’s likely growth trajectory over the forecast period. The major drivers and restraints affecting the global viral vector manufacturing market are analyzed in detail in the report. The report also takes a look at the major competitive factors defining the viral vector manufacturing market’s competitive landscape and provides a profile of the leading players in the viral vector manufacturing market. Thus, the report provides a thorough look at the global viral vector manufacturing market through all sides and perspectives.
Viral vector manufacturing has become an important process for the healthcare sector in recent years due to the growing demand for gene therapy. Gene therapy involves replacing a part of the genetic structure of the patient with new genes taken from a different organism. These genetic snippets are known as viral vectors. The growing demand for gene therapy from developed countries around the world is likely to be a major driver for the global viral vector manufacturing market over the forecast period.
On the other hand, difficulties in producing viral vectors and the absence of the appropriate tools are likely to be the key restraints acting against the global viral vector manufacturing market over the forecast period. Many companies in the global viral vector manufacturing market are taking steps to counter the difficulties in producing viral vectors and this area is likely to remain a hive of activity in the coming years. This has also resulted in strong growth prospects for companies that can develop effective viral vector manufacturing platforms and systems and sell them to clients in drug discovery applications.
Leading players in the global viral vector manufacturing market include Kaneka Eurogentec S.A., REGENXBIO Inc., Cobra Biologics, Cell and Gene Therapy Catapult, Brammer Bio, FinVector Vision Therapies, uniQure N.V., Spark Therapeutics Inc., Oxford BioMedica, General Electric Company, Merck KGaA, Lonza, Sanofi, and Fujifilm Diosynth Biotechnologies U.S.A. Inc.
In October 2019, Sanofi announced plans to reorient a vaccine plant in France into a gene therapy manufacturing operation, including viral vectors. The company aims to get ahead in the field of gene therapy in the coming years with the help of investments like this.
The same month, GE Healthcare Life Sciences launched KUBio box, a readymade environment for manufacturing viral vectors and gene therapies based on the same. The KUBio box is expected to speed up the market time of viral vector-based gene therapies and enable increased capacity.
The global viral vector manufacturing market is segmented on the basis of type, disease, application, end use, and region.
By type, the global viral vector manufacturing market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The retroviral vectors segment is further sub-segmented into lentiviral vectors and gamma-retroviral vectors. The retroviral vectors segment holds the largest share in the global viral vector manufacturing market. Retroviruses contain the enzyme reverse transcriptase, which enables easy assimilation into the host DNA. This has driven the demand for retroviral vectors. The adenoviral vectors segment is also expected to exhibit rapid growth over the forecast period.
By disease, the global viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and others.
By application, the market is segmented into gene therapy and vaccinology.
By end use, the global viral vector manufacturing market is segmented into pharma and biotech companies, research institutes, and others.
The Americas is anticipated to dominate the global viral vector manufacturing market over the forecast period, followed by Europe. North America is the major regional market for viral vector manufacturing due to the mature and widespread life sciences sector in the region. The increasing access to genetic therapy is expected to be a major driver for the global viral vector manufacturing market. The U.S. is likely to be a major regional market for viral vector manufacturing.
Europe is also a major regional market, driven by the strong life sciences industry in the region. The UK, Germany, and France are likely to be major regional markets over the forecast period.
The Asia Pacific market for viral vector manufacturing is also likely to grow over the forecast period at a strong growth rate. Countries such as China, India, and Japan are likely to play an important role in the market’s growth in the region.
OBTAIN RESEARCH REPORT DETAILS WITH TOC @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312